Company Filing History:
Years Active: 2013-2025
Title: William R. Shanahan: Innovator in S1P Receptor-Associated Treatments
Introduction
William R. Shanahan is a notable inventor based in Del Mar, California. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of conditions related to the sphingosine 1-phosphate subtype 1 (S1P) receptor. With a total of 7 patents to his name, his work has the potential to impact various autoimmune and inflammatory diseases.
Latest Patents
Shanahan's latest patents focus on methods of treating disorders associated with the S1P receptor. These methods involve prescribing and administering a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid, also known as Compound 1. The treatment is aimed at individuals suffering from a range of conditions, including autoimmune diseases, inflammatory disorders, and various cancers. The dosage typically ranges from about 1.5 to about 2.5 mg of Compound 1, addressing diseases mediated by lymphocytes, such as rheumatoid arthritis, Crohn's disease, and multiple sclerosis.
Career Highlights
Throughout his career, William R. Shanahan has worked with prominent companies in the pharmaceutical industry. Notable among these are Arena Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc. His experience in these organizations has contributed to his expertise in developing innovative treatments.
Collaborations
Shanahan has collaborated with several professionals in his field, including Alan Glicklich and Maria Matilde Sanchez Kam. These partnerships have likely enhanced his research and development efforts, leading to advancements in his patented methods.
Conclusion
William R. Shanahan stands out as an influential inventor in the pharmaceutical industry, particularly in the realm of S1P receptor-associated treatments. His innovative approaches and collaborations have the potential to significantly improve the management of various complex diseases.